What Visibly Ages Skin — and the Peptide Research Aimed at Each Part of It

The short version

Visible skin aging comes from a handful of things going on underneath the surface: the scaffolding of collagen and elastin that keeps skin firm breaks down faster than the body rebuilds it, pigment-making cells (melanocytes) start behaving unevenly, and wound repair simply gets slower. This site looks at three peptides that researchers have studied in connection with those processes: GHK-Cu, a copper-binding tripeptide with the deepest evidence base here; GLOW, a combination blend built around GHK-Cu plus two other repair peptides; and Melanotan II, a pigment-signaling peptide with a very different, and considerably riskier, research story.

None of these are medicines you can be prescribed for anti-aging, and this site does not sell, source, or recommend any of them. What it does is read the actual published research — case reports, cell studies, small human trials — and explain, in plain terms, what was tested, on whom, and what the numbers actually showed. Where people in research communities report their own experiences, that is labeled clearly as anecdote, never as evidence.

What visibly ages skin — and where the research looks

Three structural changes account for most of what people describe as "aging skin." First, collagen and elastin synthesis slows — the proteins that keep skin firm and elastic decline in both production and quality, and matrix-degrading enzymes (MMPs) start to outpace the enzymes that hold them in check. Second, pigment regulation becomes uneven — melanocytes that once produced pigment evenly begin to cluster, leading to age spots and blotchiness, or in some contexts researchers study whether pigment signaling can be deliberately activated. Third, repair slows down — smaller injuries, sun damage, and everyday wear take longer to resolve as fibroblast and vascular repair mechanisms lose efficiency with age.

GHK-Cu's research sits mostly in the first bucket: a 2015 review notes that plasma GHK itself declines from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, alongside laboratory evidence that the copper-bound peptide stimulates collagen, elastin, and proteoglycan synthesis in skin cells ^[4]. GLOW's rationale layers two additional repair-focused peptides on top of that collagen story. Melanotan II sits in the second bucket — pigment regulation — through a completely different receptor system, and its research record includes far more serious safety findings than the other two.

What are research peptides?

Peptides are short chains of amino acids, the same building blocks that make up every protein in the body. Some, like GHK-Cu, are naturally occurring — the GHK sequence is found in human plasma, saliva, and inside type I collagen itself, and only becomes a bioactive "peptide" of research interest once it is isolated and studied at concentrations well above what circulates naturally. Others, like Melanotan II, are synthetic analogs engineered in a lab to bind a natural receptor more powerfully or more durably than the hormone the body actually makes.

One compound on this site, GLOW, is not a peptide at all in the strict sense — it is a blend, a supplier- or clinic-formulated mixture of three separate peptides sold together on the theory that their individual mechanisms complement each other. No clinical trial has ever tested that combination as a single product; every claim about it is extrapolated from studies of its individual ingredients. This site is explicit about that distinction on every page, because conflating a tested single molecule with an untested combination is one of the more common ways peptide marketing overstates its evidence.

How to read this site

Each compound gets its own page with the same arc: what it is chemically, how it is thought to work, what the actual published research found (with a numbered citation for every specific claim), what people in research-use and skincare communities report — always labeled anecdotal, not clinical evidence — and the safety cautions the literature raises. A comparison page lines the three up side by side, an FAQ answers the questions people bring most often, and every citation used anywhere on the site is collected on the references page. Nothing on this site is a recommendation to use any of these compounds, and no page names a human dose outside the context of describing what a specific study used.